









































































































# Canaccord Genuity US IB Snapshot

## 152 Transactions Over the Last Twelve Months

### Selected Recent Transactions

|   |  |   |  |   |  |  |  |   |
|---|--|---|--|---|--|--|--|---|
| <br><b>Saliarius Pharmaceuticals</b><br>Financial Advisor on merger with<br><br><b>Decoy Therapeutics</b><br>Pending<br>June 2025   | <br><b>zeelo</b><br>\$23,000,000<br>Financial Advisor on Series B fundraise led by<br><br><b>BlueEarth Therapeutics</b><br>with participation from existing investors<br>June 2025 | <br><b>CIRCLE</b><br>\$1,212,100,000<br>IPO<br>Co-Manager<br>June 2025   | <br><b>OKLO</b><br>\$460,000,020<br>Follow-On Offering<br>Co-Manager<br>June 2025   | <br><b>moody's</b><br>Financial Advisor on sale to<br><br><b>ASCENDION</b><br>June 2025   | <br><b>Etsy</b><br>\$700,000,000<br>Conv. Notes Offering<br>Co-Manager<br>June 2025  | <br><b>chime</b><br>\$993,600,000<br>IPO<br>Co-Manager<br>June 2025   | <br><b>IREN</b><br>\$550,000,000<br>Conv. Notes Offering<br>Co-Manager<br>June 2025   | <br><b>omada</b><br>\$172,615,000<br>IPO<br>Co-Manager<br>June 2025  |
| <br><b>Button</b><br>Financial Advisor on strategic growth investment from<br><br><b>PSG</b><br>June 2025                           | <br><b>Life360</b><br>\$320,000,000<br>Conv. Notes Offering<br>Co-Manager<br>June 2025  | <br><b>ASP isotopes</b><br>\$50,000,000<br>Registered Direct Offering<br>Joint Bookrunner<br>June 2025   | <br><b>D:wave</b><br>\$400,000,000<br>ATM Offering<br>Co-Agent<br>June 2025   | <br><b>XponentL Data</b><br>Financial Advisor on sale to<br><br><b>genpact</b><br>June 2025   | <br><b>galaxy</b><br>\$683,638,373<br>Follow-On Offering<br>Joint Bookrunner<br>May 2025   | <br><b>Hinge Health</b><br>\$502,908,800<br>IPO<br>Co-Manager<br>May 2025   | <br><b>klaviyo</b><br>\$372,948,652<br>Follow-On Offering<br>Co-Manager<br>May 2025   | <br><b>CHEMISTRY</b><br>Financial Advisor on strategic investment from<br><br><b>BREWwater</b><br>May 2025    |
| <br><b>WAVSTAR</b><br>\$557,031,250<br>Follow-On Offering<br>Co-Manager<br>May 2025  | <br><b>eToro</b><br>\$712,996,440<br>Initial Public Offering<br>Co-Manager<br>May 2025  | <br><b>Gimmel</b><br>Financial Advisor on sale to<br><br><b>Morae</b><br>May 2025                                       | <br><b>hims &amp; hers</b><br>\$1,000,000,000<br>Conv. Notes Offering<br>Co-Manager<br>May 2025   | <br><b>Cognito Forms</b><br>Financial Advisor on merger with<br><br><b>INVERNESS GRAHAM</b><br>May 2025   | <br><b>Exagen</b><br>\$20,225,625<br>Follow-On Offering<br>Sole Bookrunner<br>May 2025   | <br><b>StrategyB</b><br>\$21,000,000,000<br>ATM Offering<br>Co-Agent<br>May 2025  | <br><b>NEOCOL</b><br>Financial Advisor on investment from<br><br><b>SHAMROCK CAPITAL</b><br>May 2025 | <br><b>TriSalus Life Sciences</b><br>\$22,000,000<br>PIPE<br>Sole Agent<br>April 2025  |
| <br><b>Semler Scientific</b><br>\$500,000,000<br>ATM Offering<br>Co-Agent<br>April 2025  | <br><b>VIZSLA SILVER CORP</b><br>\$200,000,000<br>ATM Offering<br>Co-Lead Agent<br>April 2025   | <br><b>apex capital</b><br>Financial Advisor on acquisition of<br><br><b>Jumia</b><br>April 2025                    | <br><b>cleno</b><br>\$25,000,000<br>ATM Offering<br>Sole Agent<br>April 2025  | <br><b>sportradar</b><br>\$595,125,000<br>Follow-On Offering<br>Co-Manager<br>April 2025   | <br><b>CHANNELFACTORY</b><br>Financial Advisor on significant investment from<br><br><b>TRUELINK CAPITAL</b><br>April 2025 | <br><b>ASP isotopes</b><br>\$25,000,000<br>ATM Offering<br>Sole Agent<br>April 2025   | <br><b>gaiascope</b><br>Financial Advisor on sale to<br><br><b>ENGIE</b><br>April 2025           | <br><b>Lucid diagnostics</b><br>\$17,250,000<br>Follow-On Offering<br>Sole Bookrunner<br>April 2025  |
| <br><b>ENTERPRISE SOLUTIONS</b><br>Financial Advisor on sale to<br><br><b>White Mountains Partners</b><br>April 2025            | <br><b>EverService</b><br>Financial Advisor on sale of its customer engagement division to<br>Undisclosed buyer<br>April 2025   | <br><b>StrategyB</b><br>\$21,000,000,000<br>ATM Offering<br>Co-Agent<br>March 2025   | <br><b>CONVERGE TECHNOLOGY</b><br>C\$1,336,100,000<br>Lead Financial Advisor on sale to<br><br><b>HITC CAPITAL</b><br>April 2025 | <br><b>INFLECTION POINT II</b><br>\$870,000,000<br>Capital Markets Advisor on merger with<br><br><b>USA Rare Earth</b><br>March 2025        | <br><b>20E</b><br>Financial Advisor on strategic investment from<br><br><b>INSIGHT PARTNERS</b><br>March 2025              | <br><b>EZCORP</b><br>\$300,000,000<br>Senior Debt Offering<br>Joint Bookrunner<br>March 2025  | <br><b>SEQUENTIAL TECH</b><br>Financial Advisor on sale to<br><br><b>FUSION</b><br>March 2025    | <br><b>DAKOTA GOLD</b><br>\$35,092,000<br>Follow-On Offering<br>Joint Bookrunner<br>March 2025   |
| <br><b>CleanPlanet</b><br>\$30,000,000<br>Financial Advisor on growth equity investment from<br><br><b>nuveen</b><br>March 2025 | <br><b>BRIDGER AEROSPACE</b><br>\$100,000,000<br>ATM Offering<br>Co-Agent<br>March 2025   | <br><b>REPDATA</b><br>Financial Advisor on growth investment from<br><br><b>MOUNTAIN GATE CAPITAL</b><br>March 2025 | <br><b>kipi.ai</b><br>Financial Advisor on sale to<br><br><b>WNS</b><br>March 2025   | <br><b>Lucid diagnostics</b><br>\$15,333,254<br>Registered Direct Offering<br>Sole Placement Agent<br>March 2025   | <br><b>Analytics8</b><br>Financial Advisor on growth capital investment from<br><br><b>Boathouse</b><br>February 2025      | <br><b>WAYSTAR</b><br>\$920,000,000<br>Follow-On Offering<br>Co-Manager<br>February 2025  | <br><b>vistar media</b><br>Financial Advisor on sale to<br><br><b>T-Mobile</b><br>February 2025  | <br><b>StrategyB</b><br>\$2,000,000,000<br>Conv. Notes Offering<br>Co-Manager<br>February 2025   |
| <br><b>guidance</b><br>Financial Advisor on sale to<br><br><b>one magnify</b><br>February 2025                                  | <br><b>Neuronetics</b><br>\$20,700,000<br>Follow-On Offering<br>Sole Bookrunner<br>February 2025  | <br><b>keymark</b><br>Financial Advisor on strategic partnership with<br><br><b>SourceCapital</b><br>February 2025  | <br><b>GH RESEARCH</b><br>\$150,000,000<br>Follow-On Offering<br>Co-Lead Manager<br>February 2025   | <br><b>SES</b><br>\$150,000,000<br>ATM Offering<br>Co-Agent<br>February 2025   | <br><b>GO Banking Rates</b><br>Financial Advisor on sale to<br><br><b>Gen</b><br>January 2025                              | <br><b>Semler Scientific</b><br>\$100,000,000<br>Conv. Notes Offering<br>Co-Manager<br>January 2025   | <br><b>dysrupt</b><br>Financial Advisor on sale to<br><br><b>PUBLICIS GROUPE</b><br>January 2025 | <br><b>US ANCHORS</b><br>Financial Advisor on sale to<br><br><b>KINDERHOOK PROPERTIES</b><br>January 2025 |
| <br><b>VERTICAL</b><br>\$90,000,000<br>Follow-On Offering<br>Joint Bookrunner<br>January 2025  | <br><b>Ridgemont EQUITY PARTNERS</b><br>Financial Advisor on investment from<br><br><b>SIG</b><br>January 2025   | <br><b>IREN</b><br>\$1,000,000,000<br>ATM Offering<br>Co-Agent<br>January 2025   | <br><b>repsly</b><br>Financial Advisor on recapitalization by<br><br><b>QUADRILLA CAPITAL</b><br>January 2025                    | <br><b>WiseMusic Group</b><br>Financial Advisor on sale of its Digital Education division to<br><br><b>ACHIEVE PARTNERS</b><br>January 2025 | <br><b>arbe</b><br>\$33,062,499<br>Registered Direct Offering<br>Sole Bookrunner<br>January 2025   | <br><b>AMERESCO</b><br>Financial Advisor on divestiture of its Applied Energy Group business unit to<br><br><b>ICF</b><br>January 2025 | <br><b>ServiceTitan</b><br>\$718,520,000<br>IPO<br>Passive Bookrunner<br>December 2024  | <br><b>Syapse</b><br>Financial Advisor on acquisition by<br><br><b>n^</b><br>December 2024                |

# Canaccord Genuity

## US IB Snapshot



### Ranked #1 for US Middle-Market TMT Activity<sup>1</sup>

| Rank | Firm Name             | # of Transactions<br>LTM 6/30/25 | Rank | Firm Name             | # of Transactions<br>2022-2024 |
|------|-----------------------|----------------------------------|------|-----------------------|--------------------------------|
| 1    | Canaccord Genuity     | 53                               | 1    | Canaccord Genuity     | 158                            |
| 2    | Houlihan Lokey        | 18                               | 2    | Houlihan Lokey        | 64                             |
| 3    | Raymond James         | 12                               | 3    | Raymond James         | 51                             |
| 4    | Baird                 | 10                               | 4    | Lincoln International | 47                             |
| 5    | Lincoln International | 9                                | 5    | William Blair         | 46                             |
| 5    | Moelis                | 9                                | 6    | Moelis                | 38                             |
| 7    | Morgan Stanley        | 8                                | 7    | Morgan Stanley        | 30                             |
| 7    | Evercore              | 8                                | 8    | Stifel                | 28                             |
| 7    | Piper Sandler         | 8                                | 9    | Goldman Sachs         | 27                             |
| 10   | Guggenheim            | 7                                | 9    | Jefferies             | 27                             |
| 11   | Goldman Sachs         | 6                                | 11   | Piper Sandler         | 25                             |
| 11   | Stifel                | 6                                | 11   | Evercore              | 25                             |

### Ranked #1 for US Middle-Market Media & Information Services Activity<sup>1</sup>

| Rank | Firm Name             | # of Transactions<br>LTM 6/30/25 | Rank | Firm Name             | # of Transactions<br>2022-2024 |
|------|-----------------------|----------------------------------|------|-----------------------|--------------------------------|
| 1    | Canaccord Genuity     | 40                               | 1    | Canaccord Genuity     | 128                            |
| 2    | Houlihan Lokey        | 17                               | 2    | Houlihan Lokey        | 51                             |
| 3    | Raymond James         | 13                               | 3    | Moelis                | 27                             |
| 4    | Lincoln International | 11                               | 3    | Lincoln International | 27                             |
| 5    | Moelis                | 10                               | 5    | Raymond James         | 23                             |
| 6    | TobinLeff             | 9                                | 6    | JEGI CLARITY          | 22                             |
| 6    | JEGI CLARITY          | 9                                | 7    | TobinLeff             | 21                             |
| 8    | Evercore              | 8                                | 8    | GP Bullhound          | 20                             |
| 8    | William Blair         | 8                                | 8    | William Blair         | 20                             |
| 10   | Generational          | 6                                | 10   | Stifel                | 18                             |

### Ranked #1 for US Middle-Market Digital & Tech-Enabled Healthcare Activity<sup>2</sup>

| Rank | Firm Name                      | # of Transactions<br>LTM 6/30/25 | Rank | Firm Name             | # of Transactions<br>2022-2024 |
|------|--------------------------------|----------------------------------|------|-----------------------|--------------------------------|
| 1    | Canaccord Genuity              | 7                                | 1    | Canaccord Genuity     | 30                             |
| 2    | Houlihan Lokey                 | 3                                | 2    | Houlihan Lokey        | 9                              |
| 2    | Stifel                         | 3                                | 3    | William Blair         | 6                              |
| 4    | Cain Brothers                  | 2                                | 3    | Raymond James         | 6                              |
| 4    | Lincoln International          | 2                                | 3    | TripleTree            | 6                              |
| 4    | Raymond James                  | 2                                | 6    | Guggenheim            | 5                              |
| 4    | Healthcare Growth Partners     | 2                                | 6    | Novistra              | 5                              |
| 4    | Jefferies                      | 2                                | 6    | Lincoln International | 5                              |
| 9    | Oppenheimer                    | 1                                | 9    | Stifel                | 4                              |
| 9    | Ernst & Young Capital Advisors | 1                                | 9    | KeyBanc               | 4                              |

### Leading Global Underwriter Since 2022<sup>3</sup>

| Global Rank | Firm Name         | Total Deals | Bookrun Deals |
|-------------|-------------------|-------------|---------------|
| 1           | Canaccord Genuity | 1,147       | 872           |
| 2           | Goldman Sachs     | 1,093       | 1,065         |
| 3           | JPMorgan          | 1,093       | 1,072         |
| 4           | Morgan Stanley    | 1,003       | 968           |
| 5           | BofA Securities   | 928         | 885           |
| 6           | Citi              | 771         | 754           |
| 7           | UBS               | 617         | 594           |
| 8           | Jefferies         | 611         | 603           |
| 9           | Stifel            | 548         | 369           |
| 10          | Barclays          | 517         | 488           |

<sup>1</sup>Source: PitchBook for the time period 1/1/22-6/30/25. Transaction totals represent US M&A/Control Transactions, All Buyout Types, and Growth/Expansion transactions <\$500M in the Technology, Media & Telecommunications (TMT) and Media & Information Services segments as classified by PitchBook

<sup>2</sup>Source: PitchBook for the time period 1/1/22-6/30/25. Transaction totals represent US M&A/Control transactions, All Buyout Types, and Growth/Expansion transactions <\$500M in the Digital Health, Tech Healthcare, and Healthcare-focused Technology, Media & Telecommunications, and Media & Information Services segments as classified by PitchBook

<sup>3</sup>Source: Dealogic as of 6/30/25  
LTM: Last Twelve Months

# Canaccord Genuity

## US IB Snapshot



Canaccord Genuity is a full-service investment bank with a broad range of offerings focused on serving growth companies in the middle market. During the twelve months ended June 30, 2025, an increase in Equity Capital Markets transactions, along with steady M&A activity, drove our US investment banking team's robust closed deal volume and active client engagement:

- 152 total transactions for 126 different corporate clients, including 150 closed transactions and two announced and pending
- 70 advisory engagements, which ranged from minority raises, strategic sales, and private equity recaps to corporate divestiture and take-private transactions
- Added senior investment banking professionals with diverse experience, including Digital and Tech-Enabled Healthcare, Aerospace and Defense, Consumer Services, Application Software, and Infrastructure
- As part of the #1 ranked most active global underwriter operation since 2022, our US Equity Capital Markets Group completed 82 transactions in the past twelve months:
  - Underwriter on 51 capital markets transactions, including book-runner on 22 equity offerings, raising more than \$21.6 billion in cumulative proceeds for 37 different issuers
  - Three private placements raising an aggregate of nearly \$42 million
  - Managing 25 ATM programs for a total value of more than \$69.5 billion

Canaccord Genuity's US investment banking team leverages deep industry expertise across a broad universe of practices:

- TMMIS (Technology, Media, Marketing, and Information Services)
- Healthcare (Biotechnology, Biopharmaceuticals, Digital Health, IT, Services, Medical Technologies, Diagnostics, and Cannabis)
- Consumer (Health & Wellness, Home & Auto, Food & Beverage, Services, and Emerging Brands)
- Sustainability (Advanced Materials, Building Technologies, Mobility and Autonomy, Renewables, Distributed Generation and Energy Storage, Industrial and Infrastructure Services, Circular Economy) and Industrial Technologies, including Aerospace & Defense (Aerospace Services, Machining and Engines, Defense Products, Communications and Intelligence, Defense Technology, and Security Products and Services)

Our track record of success is recognized by the financial sponsor community. Approximately half of our engagements involve representing investor-backed companies. Additionally, our in-depth industry coverage continues to position Canaccord Genuity's US investment banking team as the advisor of choice for founder and management-owned businesses.

Canaccord Genuity's US investment banking team has nearly 170 professionals in Boston, Charlotte, Chicago, Nashville, New York, and San Francisco, among other locations. We operate as part of a global capital markets business that provides our clients with the benefit of extensive resources, expertise, and relationships from across our operations in North America, the UK, Europe, Asia, and Australia.

We welcome the opportunity to discuss your business and your strategic objectives.

**About Canaccord Genuity Group Inc.:** Through its principal subsidiaries, Canaccord Genuity Group Inc. is a leading independent, full-service financial services firm, with operations in two principal segments of the securities industry: wealth management and capital markets. Since its establishment in 1950, the Company has been driven by an unwavering commitment to building lasting client relationships. We achieve this by generating value for our individual, institutional, and corporate clients through comprehensive investment solutions, brokerage services, and investment banking services. The Company has Wealth Management offices located in Canada, the UK, Guernsey, Jersey, the Isle of Man, and Australia. The international capital markets division operates in North America, the UK, Europe, Asia, and Australia. Canaccord Genuity Group Inc. is publicly traded under the symbol CF on the TSX.

Information on this page is sourced from Canaccord Genuity's proprietary database.

This document is provided for informational purposes only and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited. As a result, the securities discussed in this document may not be eligible for sale in some jurisdictions. This document is not, and under no circumstances should be construed as, a solicitation to act as a securities broker or dealer in any jurisdiction by any person or company that is not legally permitted to carry on the business of a securities broker or dealer in that jurisdiction. Investors should obtain advice based on their own individual circumstances before making an investment decision.

To the fullest extent permitted by law, neither Canaccord Genuity, nor its affiliates nor any other person accepts any liability whatsoever for any direct or consequential loss arising from any use of the information contained in this document.

This publication is a brief summary and does not purport to contain all available information on the subjects covered. Further information is available on request.

Copyright © Canaccord Genuity LLC, 2025. Member FINRA/SIPC.

All rights reserved. All material presented in this document, unless specifically indicated otherwise, is under copyright to Canaccord Genuity, a division of Canaccord Genuity Group Inc., Canaccord Genuity Limited, and Canaccord Genuity LLC. None of the material, nor its content, nor any copy of it, may be altered in any way, or transmitted to or distributed to any other party, without the prior express written permission of the entities listed above.

# Canaccord Genuity US IB Snapshot



## Canaccord Genuity US Senior Investment Banking Team

**Jeff Barlow, CFA**  
CEO,  
Canaccord Genuity LLC (US)  
Boston  
[jbarlow@cgf.com](mailto:jbarlow@cgf.com)

**Sanjay Chadda**  
Managing Director,  
Co-Head US & Technology, Media,  
Marketing, & Information Services  
Investment Banking  
New York  
[schadda@cgf.com](mailto:schadda@cgf.com)

**Dan Coyne**  
Managing Director,  
Co-Head US  
& Global Head of Sustainability  
Investment Banking  
Boston  
[dcoyne@cgf.com](mailto:dcoyne@cgf.com)

**Jen Pardi**  
Managing Director,  
Global Head of ECM &  
Co-Head of US Securities  
Boston  
[jpardi@cgf.com](mailto:jpardi@cgf.com)

### Sector Leads

**Andrew Pojani**  
Managing Director,  
Co-Head US Technology, Media,  
Marketing, & Information Services  
Investment Banking  
Boston  
[apojani@cgf.com](mailto:apojani@cgf.com)

**Fuad Sawaya**  
Managing Director,  
Vice Chairman & Global Head of  
Consumer Investment Banking  
New York  
[fsawaya@cgf.com](mailto:fsawaya@cgf.com)

**Jeff Kuhr**  
Managing Director,  
Head of US Consumer  
Investment Banking  
New York  
[jkuhr@cgf.com](mailto:jkuhr@cgf.com)

**Tom O'Connor**  
Managing Director,  
Co-Head of US Healthcare  
Investment Banking  
New York  
[toconnor@cgf.com](mailto:toconnor@cgf.com)

**Eugene Rozelman**  
Managing Director,  
Co-Head of US Healthcare  
Investment Banking  
New York  
[erozelman@cgf.com](mailto:erozelman@cgf.com)

**Matt Steere**  
Managing Director,  
Co-Head of US Healthcare  
Investment Banking  
San Francisco  
[msteere@cgf.com](mailto:msteere@cgf.com)

### Financial Sponsors Coverage

**Isaiah Knouff**  
Managing Director,  
Co-Head of Financial  
Sponsors Coverage  
Nashville  
[iknouff@cgf.com](mailto:iknouff@cgf.com)

**Amy LaBan, CFA**  
Managing Director,  
Co-Head of Financial  
Sponsors Coverage  
Chicago  
[alaban@cgf.com](mailto:alaban@cgf.com)

**Bryan Cummings**  
Managing Director  
New York  
[bcummings@cgf.com](mailto:bcummings@cgf.com)

### Product Specialists

**David Istock**  
Managing Director,  
Head of US M&A  
San Francisco  
[distock@cgf.com](mailto:distock@cgf.com)

### Senior US Team

**Irina Adler**  
Managing Director  
New York  
[iadler@cgf.com](mailto:iadler@cgf.com)

**Dennis Camporeale**  
Managing Director  
New York  
[dcamporeale@cgf.com](mailto:dcamporeale@cgf.com)

**Neeraj Chugh**  
Managing Director  
New York  
[nchugh@cgf.com](mailto:nchugh@cgf.com)

**Nick Clemens**  
Managing Director  
Charlotte  
[nclemens@cgf.com](mailto:nclemens@cgf.com)

**Christopher Heasman**  
Managing Director  
New York  
[cheasman@cgf.com](mailto:cheasman@cgf.com)

**Matthew Kebel**  
Managing Director  
New York  
[mkebel@cgf.com](mailto:mkebel@cgf.com)

**Ben Lunka**  
Managing Director  
Charlotte  
[blunka@cgf.com](mailto:blunka@cgf.com)

**Lance Maerov**  
Managing Director  
New York  
[lmaerov@cgf.com](mailto:lmaerov@cgf.com)

**Marc Marano**  
Managing Director  
Boston  
[mmarano@cgf.com](mailto:mmarano@cgf.com)

**Trevor Martin**  
Managing Director  
Boston  
[tmartin@cgf.com](mailto:tmartin@cgf.com)

**Joshua Michaels**  
Managing Director  
New York  
[jmichaels@cgf.com](mailto:jmichaels@cgf.com)

**JP Michaud**  
Managing Director  
Charlotte  
[jmichaud@cgf.com](mailto:jmichaud@cgf.com)

**Tom Murphy**  
Managing Director  
New York  
[tjmurphy@cgf.com](mailto:tjmurphy@cgf.com)

**Vik Pandit**  
Managing Director  
New York  
[vpandit@cgf.com](mailto:vpandit@cgf.com)

**Jason Partenza**  
Managing Director  
New York  
[jpartenza@cgf.com](mailto:jpartenza@cgf.com)

**Mike Raffaniello**  
Managing Director  
New York  
[mraffaniello@cgf.com](mailto:mraffaniello@cgf.com)

**Jake Rapp, CFA**  
Managing Director  
Chicago  
[jrapp@cgf.com](mailto:jrapp@cgf.com)

**Bill Schmitz**  
Managing Director  
New York  
[wschmitz@cgf.com](mailto:wschmitz@cgf.com)

**Jim Schroder**  
Managing Director  
San Francisco  
[jschroder@cgf.com](mailto:jschroder@cgf.com)

**Lexia Schwartz**  
Managing Director  
New York  
[lschwartz@cgf.com](mailto:lschwartz@cgf.com)

**Meredith Sondler-Bazar**  
Managing Director  
New York  
[msondlerbazar@cgf.com](mailto:msondlerbazar@cgf.com)

**Rohan Sura**  
Managing Director  
New York  
[rsura@cgf.com](mailto:rsura@cgf.com)

**Theodora Townsend**  
Managing Director  
New York  
[thtownsend@cgf.com](mailto:thtownsend@cgf.com)

**Edin Trto**  
Managing Director  
New York  
[etrto@cgf.com](mailto:etrto@cgf.com)

**Mark Turco**  
Managing Director  
Nashville  
[mturco@cgf.com](mailto:mturco@cgf.com)

**Maurice Watkins**  
Managing Director  
New York  
[mwatkins@cgf.com](mailto:mwatkins@cgf.com)

**Andrew Delio**  
Director  
New York  
[adelio@cgf.com](mailto:adelio@cgf.com)

**Andrew Cohen**  
Director  
New York  
[acohen@cgf.com](mailto:acohen@cgf.com)

**Chris DiPietro**  
Director  
Boston  
[cdipietro@cgf.com](mailto:cdipietro@cgf.com)

**Fred Fang**  
Director  
Nashville  
[ffang@cgf.com](mailto:ffang@cgf.com)

**Matt Hoffman**  
Director  
New York  
[mhoffman@cgf.com](mailto:mhoffman@cgf.com)

**Charles Jang**  
Director  
New York  
[cjang@cgf.com](mailto:cjang@cgf.com)

**Wesley Rossiter**  
Director  
Boston  
[wrossiter@cgf.com](mailto:wrossiter@cgf.com)

**Peter Sullivan**  
Director  
Chicago  
[psullivan@cgf.com](mailto:psullivan@cgf.com)

**Charles Wong**  
Director  
New York  
[cwwong@cgf.com](mailto:cwwong@cgf.com)